ClinicalTrials.gg
CompletedNCT07552779Updated Jul 28, 2026

A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of Ibuzatrelvir

A Phase 1 interventional study of Ibuzatrelvir co-process API film coated tablet and Ibuzatrelvir filmcoated tablet in Coronavirus Disease 2019, Coronavirus Disease 2019 (COVID-19) and COVID-19 (Coronavirus Disease 2019), sponsored by Pfizer. Completed at 1 site in Belgium. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies in COVID-19 by Pfizer — 4 open to participants now, 10 under way, 3 of them phase 3. COVID-19 · Pfizer.

Enrollment
22nd of 41
17 · median 20
Started
2026
with 1 other
Phase 1
25 of 69
none open now
Registered
68th of 69
by date

Among the 69 studies in COVID-19 by Pfizer, this one is the 22nd largest by enrollment of the 41 interventional ones that give a count, is one of 2 that started in 2026, is one of 25 in phase 1, and was the 68th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

4 of the 69 studies in COVID-19 by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in COVID-19 by Pfizer, or all of them as a file.
02

Study summary

Healthy adults will be enrolled into this open-label, Phase 1 research study. Participants will spend about 9 nights and 10 days in the clinical research unit (CRU) and the total time in the study will be about 11 weeks.

The goal of this clinical trial is to compare how much of the study drug ibuzatrelvir is in participants' blood after taking one of the two different types of tablets containing the same amount of ibuzatrelvir without food. The study will also measure how much ibuzatrelvir is in participants' blood after taking one type of the tablets dispersed in water and when one type of the tablets is taken with food. This study drug is taken by mouth.

Read the detailed description

This is a Phase 1, open-label, randomized, 4-period, 6-sequence crossover study in healthy adult participants. The goal of this clinical study is to compare how much of the oral (taken by mouth) study drug ibuzatrelvir is in participants' blood after taking one of the two different types of tablets containing the same amount of ibuzatrelvir without food (fasted). The study will also measure how much ibuzatrelvir is in participants' blood after taking one type of the tablets dispersed in water and when one type of the tablets is taken with food. Safety and tolerability after taking the study medication will also be assessed.

Healthy adult participants will be screened within 28 days prior to the first day of study treatment. Participants will take one dose of study drug on the first day of each of 4 dosing periods that are 2-3 days each. Participants will remain in the clinical research unit (CRU) from Day -1 of Period 1 until completion of procedures on Day 3 of Period 4. This means that participants will stay in the CRU for a total of 9 nights and 10 days. The follow-up phone call will take place approximately 28-35 days after the last dose of study drug. The total time in the study is about 10-11 weeks.

The study treatments are:

Treatment A: ibuzatrelvir (original) fasted Treatment B: ibuzatrelvir (new) fasted Treatment C: ibuzatrelvir (new as dispersion in water) fasted Treatment D: ibuzatrelvir (new) fed

This is a crossover study which means that the treatment groups will receive the same treatments (A, B, C, and D) in a different order during the 4 dosing periods.

Group Period 1 Period 2 Period 3 Period 4

  1. A (fasted) B (fasted) C (fasted) D (Fed)
  2. A (fasted) C (fasted) B (fasted) D (Fed)
  3. B (fasted) A (fasted) C (fasted) D (Fed)
  4. B (fasted) C (fasted) A (fasted) D (Fed)
  5. C (fasted) A (fasted) B (fasted) D (Fed)
  6. C (fasted) B (fasted) A (fasted) D (Fed)

During the screening and time in the CRU participants will have:

  • Blood and urine samples collected for safety lab tests
  • Pharmacokinetics (PK) blood samples collected to detect concentrations of ibuzatrelvir (up to 40 samples)
  • Up to 8 electrocardiograms (ECGs - records the electrical signals controlling your heart)
  • To fast (not eat) for at least 10 hours overnight before 3 of the 4 doses

Approximately 18 participants will be enrolled in the study.

03

Conditions studied

  • Coronavirus Disease 2019
  • Coronavirus Disease 2019 (COVID-19)
  • COVID-19 (Coronavirus Disease 2019)
  • Upper Respiratory Tract Infections
  • Respiratory Tract Infection
  • Respiratory Tract Diseases
  • COVID-19
  • COVID-19 Infection
  • COVID-19 SARS-CoV-2 Infection
  • Pneumonia
  • Lung Diseases

Keywords

  • COVID-19 infection
  • Pneumonia
  • Respiratory tract infections
  • Coronavirus infection
  • RNA virus infection
  • Lung disease
  • Pneumonia, viral
  • Infections
  • Viral protease inhibitor
  • Protease inhibitor
  • Enzyme inhibitor
  • Anti-viral agents
  • Anti-infectives
  • Ibuzatrelvir
  • COVID-19
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years of age or older (or the minimum age of consent in accordance with local regulations) at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and ECGs.
  2. of 16-32 kg/m2; and a total body weight >45 kg.
  3. Participants who are capable of giving signed and willing and able to comply with all scheduled visits, treatment plans, laboratory tests, lifestyle considerations, and other study procedures.

Exclusion criteria

Exclusion Criteria

  1. Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).

    • Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).
    • History of infection, , or ; positive testing for HIV, HBsAg, or HCVAb. Hepatitis B vaccination is allowed.
  2. Any medical or psychiatric condition including any active suicidal ideation in the past year or suicidal behavior in the past 5 years or laboratory abnormality or other conditions that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  3. Use of prescription or nonprescription drugs and dietary and herbal supplements within 14 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention with the exception of moderate or strong inducers which are prohibited within 14 days plus 5 half-lives prior to the first dose of study intervention.
  4. Previous administration of an product (drug or vaccine) within 30 days or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer).
  5. Participation in studies of other investigational products (drug or vaccine) at any time during participation in this study.
  6. A positive urine drug test. A single repeat for positive drug screen may be allowed.
  7. Screening supine BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic) for participants \<60 years; and ≥150/90 mm/Hg for participants ≥60 years old, following at least 5 minutes of supine rest. If systolic BP is ≥140 or 150 mm Hg (based on age) or diastolic ≥90 mm Hg, the BP should be repeated 2 more times and the average of the 3 BP values should be used to determine the participant's eligibility.
  8. An \<60 mL/min/1.73 m² as determined by the CKD-EPI equation using Screat.
  9. Standard 12 lead that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results (including, but not limited to, >450 ms, complete LBBB, signs of an acute or indeterminate age myocardial infarction, ST segment and/or T wave changes suggestive of myocardial ischemia, second or third degree AV block, or serious bradyarrhythmias or tachyarrhythmias). If QTcF exceeds 450 ms, or QRS exceeds 120 ms, the ECG should be repeated twice and the average of the 3 QTcF or QRS values used to determine the participant's eligibility. Computer interpreted ECGs with abnormal findings should be overread by an investigator experienced in reading ECGs before excluding a participant.
  10. Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary:

    • , AST, T Bili >1.5× .
  11. History of alcohol abuse or repeated binge drinking and/or any other illicit drug use or dependence within 6 months of screening. Binge drinking is defined as a pattern of 5 (male) and 4 (female) or more alcoholic drinks in about 2 hours. As a general rule, alcohol intake should not exceed 14 units per week (1 unit = 8 ounces (240 mL) beer, 1 ounce (30 mL) of 40% spirit, or 3 ounces (90 mL) of wine).
  12. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.
  13. Use of tobacco/nicotine containing products in excess of the equivalent of 5 cigarettes/day or 2 chews of tobacco/day.
  14. History of sensitivity reactions to ibuzatrelvir or any of the formulation components of ibuzatrelvir.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Treatment A

    single dose of ibuzatrelvir original tablet formulation in the fasted state on Day 1 of the treatment period

    Drug: Ibuzatrelvir co-process API film coated tablet

  • Experimental
    Treatment B

    single dose of ibuzatrelvir new tablet formulation in the fasted state on Day 1 of the treatment period

    Drug: Ibuzatrelvir filmcoated tablet

  • Experimental
    Treatment C

    single dose of ibuzatrelvir of the new tablet formulation dispersed in water and given in the fasted state on Day 1 of the treatment period

    Drug: Ibuzatrelvir filmcoated tablet

  • Experimental
    Treatment D

    single dose of ibuzatrelvir new tablet formulation in the fed state on Day 1 of the treatment period

    Drug: Ibuzatrelvir filmcoated tablet

Interventions

  • DrugIbuzatrelvir co-process API film coated tablet

    original

  • DrugIbuzatrelvir filmcoated tablet

    new

06

What researchers measure

Primary outcomes

  1. Plasma ibuzatrelvir AUCinf (as data permit, otherwise AUClast) in the fasted state

    Relative bioavailability of a new oral formulation of ibuzatrelvir compared to the original tablet formulation in the fasted state

    Time frame: Hour 0 pre-dose in each period and 0.5, 1, 2, 4, 6, 8, 12, 24, and 48 post-dose in each period

  2. Plasma ibuzatrelvir AUCinf (as data permit, otherwise AUClast) in the fasted state

    Relative bioavailability of a dispersion of a new oral formulation of ibuzatrelvir compared to the original tablet formulation in the fasted state

    Time frame: Hour 0 pre-dose in each period and 0.5, 1, 2, 4, 6, 8, 12, 24, and 48 post-dose in each period

  3. Plasma ibuzatrelvir Cmax in the fasted state

    Relative bioavailability of a new oral formulation of ibuzatrelvir compared to the original tablet formulation in the fasted state

    Time frame: Hour 0 pre-dose in each period and 0.5, 1, 2, 4, 6, 8, 12, 24, and 48 post-dose in each period

  4. Plasma ibuzatrelvir Cmax in the fasted state

    Relative bioavailability of a dispersion of a new oral formulation of ibuzatrelvir compared to the original tablet formulation in the fasted state

    Time frame: Hour 0 pre-dose in each period and 0.5, 1, 2, 4, 6, 8, 12, 24, and 48 post-dose in each period

Secondary outcomes

  1. Incidence of AEs, clinical laboratory measurements, vital signs, and standard 12-lead ECGs

    Evaluate the safety and tolerability of different single-dose oral treatments of ibuzatrelvir

    Time frame: Day 1-35

  2. Plasma ibuzatrelvir AUCinf (as data permit, otherwise AUClast)

    Relative bioavailability of a new oral formulation of ibuzatrelvir administered in the fed state compared to the fasted state

    Time frame: Hour 0 pre-dose in each period and 0.5, 1, 2, 4, 6, 8, 12, 24, and 48 post-dose in each period

  3. Plasma ibuzatrelvir Cmax

    Relative bioavailability of a new oral formulation of ibuzatrelvir administered in the fed state compared to the fasted state

    Time frame: Hour 0 pre-dose in each period and 0.5, 1, 2, 4, 6, 8, 12, 24, and 48 post-dose in each period

07

Study locations

1 site
  • Pfizer Clinical Research Unit - Brussels
    Brussels, Bruxelles-capitale, Région de B-1070, Belgium
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2026 to primary completion in Jun 2026, 1 month.

Of 233 industry-sponsored phase 1 interventional studies under COVID-19, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's 1 month is below that.

Counting every sponsor, half of 384 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2026
First posted
Apr 27, 2026
StartActual
Apr 13, 2026
Primary completionActual
Jun 3, 2026
CompletionActual
Jun 29, 2026
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07552779
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 27, 2026
Start date
Apr 13, 2026
Primary completion
Jun 3, 2026
Completion
Jun 29, 2026
Last update
Jul 28, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion